Therefore, this study was undertaken to benchmark the use of G-CSF prophylaxis and the risk of chemotherapy-induced FN in the absence of G-CSF prophylaxis among patients with metastatic breast cancer, colorectal cancer, lung cancer, and non-Hodgkin lymphoma (NHL) in US clinical practice. Here, CSF3 is linked to lung carcinoma.